JD Health International, Inc. (6618) AI Stock Analysis

• Market Cap: HK$134.24B
• Dividend Yield: N/A
• Average Volume (3M): 9.09M
• Price to Earnings (P/E): 28.9
• Beta (1Y): 1.52
• Revenue Growth: 6.51%
• EPS Growth: 88.28%
• Country: HK
• Employees: 3,564
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Care Facilities
• EPS (TTM): 0.74
• Shares Outstanding: 3,200,115,000
• 10 Day Avg. Volume: 5,957,392
• 30 Day Avg. Volume: 9,093,271
• PEG Ratio: -3.83
• Price to Book (P/B): 4.37
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 33.37
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$44.42
• Price Target Upside: 7.04% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4

• Rating: 80 Outperform
• Price Target: HK$46.00 ▲(10.84%Upside)

JD Health International, Inc. benefits from strong financial performance and positive earnings call outcomes, which are the primary drivers of the stock score. Technical analysis supports a positive momentum, though valuation concerns slightly dampen the overall score.

JD Health International, Inc. Business Overview & Revenue Model

Company Description

JD Health International Inc., an investment holding company, operates an online healthcare platform in the People's Republic of China. It offers pharmaceutical and healthcare products, including OTC drugs, prescription drugs, and medical devices and supplies, as well as health supplements and tonics through direct selling and an online retail pharmacy network. The company also provides online healthcare services, online consultation, hospital or doctor referral, health check-ups, genetic testing, and beauty care services; health management and intelligent healthcare solutions, as well as technical and advertising services. In addition, it offers access to medical checkups, medical aesthetics, vaccination appointments, dental care services, and nucleic acid testing tests. The company was incorporated in 2018 and is headquartered in Beijing, the People's Republic of China. JD Health International Inc. is a subsidiary of JD Jiankang Limited.

How the Company Makes Money

JD Health International, Inc. generates revenue through multiple streams, primarily revolving around its digital healthcare platforms. The company's online pharmacy business is a significant revenue driver, where it sells a wide range of pharmaceutical and healthcare products directly to consumers. Additionally, JD Health earns income through its telemedicine services, providing online consultations and medical advice, which are often monetized via service fees or subscription models. The company also partners with healthcare providers and institutions to offer comprehensive health management services. Its strategic collaborations with hospitals, clinics, and insurance companies further enhance its offerings and revenue potential. JD Health benefits from its association with JD.com, utilizing its extensive logistics network and technological infrastructure to optimize service delivery and expand its customer base.

JD Health International, Inc. Financial Statement Overview

Summary

JD Health International, Inc. has shown strong revenue growth, improved profitability, and a robust balance sheet. The company effectively manages its debt levels, ensuring financial stability. Cash flow generation is strong, supporting its operations and growth initiatives.

Income Statement

JD Health International, Inc. has demonstrated strong revenue growth over the years, with a notable increase from 2019 to 2024. Gross profit margins have remained healthy, reflecting efficient cost management. The net profit margin has improved significantly, turning from losses in earlier years to profitable outcomes in recent periods, showcasing strong profitability. EBIT and EBITDA margins have shown positive trends, indicating enhanced operational efficiency.

Balance Sheet

The company's balance sheet is robust, characterized by a high equity ratio, which indicates strong financial stability and low reliance on debt. The debt-to-equity ratio is low, suggesting prudent financial management and reduced financial risk. Return on equity has improved significantly, reflecting better utilization of shareholders' funds.

Cash Flow

JD Health International exhibits a solid cash flow position, with consistent operating cash flow generation. Free cash flow growth has been positive, indicating strong cash generation capabilities. The operating cash flow to net income ratio is healthy, underscoring efficient cash conversion. However, a slight decline in operating cash flow compared to the previous year is a point of concern.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	58.16B	53.53B	46.74B	30.68B	19.38B
Gross Profit	13.31B	11.87B	9.89B	7.20B	4.92B
EBITDA	1.38B	2.93B	-60.93M	-1.37B	364.50M
Net Income	4.16B	2.14B	380.11M	-1.07B	-17.23B
Balance Sheet
Total Assets	71.27B	64.29B	61.28B	48.00B	43.99B
Cash, Cash Equivalents and Short-Term Investments	51.24B	41.22B	47.67B	41.99B	40.30B
Total Debt	258.39M	214.75M	199.41M	201.27M	89.98M
Total Liabilities	16.03B	14.92B	16.49B	8.15B	4.74B
Stockholders Equity	55.23B	49.36B	44.78B	39.85B	39.25B
Cash Flow
Free Cash Flow	4.29B	4.54B	5.86B	2.93B	3.68B
Operating Cash Flow	4.33B	4.60B	5.91B	3.43B	3.70B
Investing Cash Flow	3.15B	-8.02B	-4.24B	-17.75B	-7.84B
Financing Cash Flow	-45.61M	-117.20M	-925.45M	-163.65M	32.03B

JD Health International, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 41.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6618, the sentiment is Positive. The current price of 41.5 is above the 20-day moving average (MA) of 41.37, above the 50-day MA of 39.92, and above the 200-day MA of 32.76, indicating a bullish trend. The MACD of 0.67 indicates Positive momentum. The RSI at 52.81 is Neutral, neither overbought nor oversold. The STOCH value of 53.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6618.

JD Health International, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6618	80 Outperform	HK$134.24B	28.90	7.98%	―	6.51%	88.28%
1951	70 Outperform	HK$8.45B	26.90	2.78%	1.93%	-1.04%	-20.43%
6078	68 Neutral	HK$9.65B	14.86	9.30%	―	7.28%	-13.77%
2273	67 Neutral	HK$8.07B	24.95	13.13%	2.40%	28.02%	19.41%
3689	66 Neutral	HK$601.91M	36.22	1.07%	8.89%	-1.20%	-87.51%
1526	66 Neutral	HK$1.72B	5.33	24.13%	4.17%	-3.85%	-19.28%
Sector *	57 Neutral	7.75B	6.71	-28.09%	5.70%	26.41%	6.62%

JD Health International, Inc. Corporate Events

JD Health Grants Over 800,000 Award Shares to Employees

JD Health International, Inc. announced the grant of 834,433 Award Shares to its employees under the Post-IPO Share Award Scheme, representing approximately 0.03% of the total issued shares. The shares will vest over various periods ranging from 0.25 to 4 years, with no performance targets attached. This move aims to incentivize employees and align their interests with the company’s growth, potentially enhancing employee retention and satisfaction.

The most recent analyst rating on (HK:6618) stock is a Buy with a HK$31.00 price target. To see the full list of analyst forecasts on JD Health International, Inc. stock, see the HK:6618 Stock Forecast page.

JD Health International Secures Shareholder Approval at AGM

JD Health International, Inc. announced the successful passing of all proposed resolutions at its Annual General Meeting held on June 20, 2025. The resolutions included the adoption of financial statements, re-election of directors, and granting of mandates for share issuance and repurchase. This outcome reflects strong shareholder support and positions the company for continued strategic initiatives and governance stability.

The most recent analyst rating on (HK:6618) stock is a Buy with a HK$31.00 price target. To see the full list of analyst forecasts on JD Health International, Inc. stock, see the HK:6618 Stock Forecast page.

JD Health Reports Strong Q1 2025 Growth and AI Advancements

JD Health International Inc. has announced significant advancements in its operations during the first quarter of 2025. The company launched several innovative drugs online and strengthened partnerships with major healthcare product companies to expand its product offerings and market reach. Additionally, JD Health made strides in medical AI, introducing the ‘AI Jingyi’ system and open-sourcing its ‘Jingyi Qianxun’ LLM, which have been well-received by healthcare professionals. Financially, the company reported a 25.5% increase in revenue and a 47.7% rise in non-IFRS profit compared to the same period in 2024, indicating strong growth and operational success.

The most recent analyst rating on (HK:6618) stock is a Buy with a HK$46.30 price target. To see the full list of analyst forecasts on JD Health International, Inc. stock, see the HK:6618 Stock Forecast page.

JD Health Announces 2025 Annual General Meeting Agenda

JD Health International, Inc. has announced its upcoming annual general meeting scheduled for June 20, 2025, in Beijing, China. Key agenda items include the adoption of the company’s financial statements for 2024, re-election of several directors, and re-appointment of Deloitte Touche Tohmatsu as auditors. The meeting will also consider granting the board authority to manage share allotments, reflecting the company’s strategic focus on maintaining robust governance and operational flexibility.